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In the brain of patients with multiple sclerosis, activated microglia/macrophages
appear in active lesions and in normal appearing white matter. However, whether
they play a beneficial or a detrimental role in the development of the pathology
remains a controversial issue. The production of pro-inflammatory molecules by
chronically activated microglial cells is suggested to contribute to the progression of
neurodegenerative processes in neurological disease. In the healthy brain, neurons
control glial activation through several inhibitory mechanisms, such as the CD200-
CD200R1 interaction. Therefore, we studied whether alterations in the CD200-
CD200R1 system might underlie the neuroinflammation in an experimental autoimmune
encephalomyelitis (EAE) model of multiple sclerosis. We determined the time course of
CD200 and CD200R1 expression in the brain and spinal cord of an EAE mouse model
from presymptomatic to late symptomatic stages. We also assessed the correlation
with associated glial activation, inflammatory response and EAE severity. Alterations in
CD200 and CD200R1 expression were mainly observed in spinal cord regions in the
EAE model, mostly a decrease in CD200 and an increase in CD200R1 expression.
A decrease in the expression of the mRNA encoding a full CD200 protein was detected
before the onset of clinical signs, and remained thereafter. A decrease in CD200 protein
expression was observed from the onset of clinical signs. By contrast, CD200R1
expression increased at EAE onset, when a glial reaction associated with the production
of pro- and anti-inflammatory markers occurred, and continued to be elevated during
the pathology. Moreover, the magnitude of the alterations correlated with severity of the
EAE mainly in spinal cord. These results suggest that neuronal-microglial communication
through CD200-CD200R1 interaction is compromised in EAE. The early decreases in
CD200 expression in EAE suggest that this downregulation might also occur in the
initial phases of multiple sclerosis, and that this early neuronal dysfunction might facilitate
the development of neuroinflammation. The increased CD200R1 expression in the EAE
model highlights the potential use of targeted agonist molecules as therapeutic tools
to control neuroinflammation. In summary, the CD200-CD200R1 system is a potential
therapeutic target in multiple sclerosis, and CD200R1 agonists are molecules that may
be worth developing in this context.
Keywords: CD200-CD200R1, EAE, multiple sclerosis, neuroinflammation, glial activation, neuron-glia
communication, neurological disease, microglia
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INTRODUCTION
Neuroinflammation plays a role in the pathogenesis and
progression of multiple sclerosis (MS), involving immune cells
from both the peripheral immune system and the central nervous
system (CNS) (González et al., 2014). Because the modulation of
neuroinflammation is considered a possible therapeutic strategy
in MS, a thorough knowledge of the cellular and molecular
mechanisms is necessary to identify candidate therapeutic targets.
To what extent microglia, the main innate immune cells of the
CNS, contribute to the development of MS is still a matter of
debate (Bogie et al., 2014; Correale, 2014; Gertig and Hanisch,
2014).
Activated microglia/macrophages are not only found in active
lesions but also in normal appearing white matter in the brains
of MS patients, which suggests that microglia are involved from
the initial stages of pathology (Allen et al., 2001; Zeis et al., 2008;
van Horssen et al., 2012; Melief et al., 2013). Microglia are crucial
in the maintenance of brain homeostasis, and activated microglia
show a wide range of molecular and functional phenotypes, from
the classically activated M1 phenotype, associated with a pro-
inflammatory effect, to the alternatively activated M2 phenotype,
associated with a beneficial effect (Napoli and Neumann, 2010;
Gertig and Hanisch, 2014). The production of pro-inflammatory
molecules by chronically activated microglial cells may contribute
to the progress of neurodegenerative processes in neurological
disease, and the inhibition of this response could be a therapeutic
target. However, microglial functions also include promotion
of neuronal survival, control of the inflammatory response,
induction of phagocytosis of cellular debris and stimulation of
tissue repair. Consequently, the precise role of microglia in the
development of MS is still controversial. An optimal therapeutic
approach targeting microglial cells could focus on modulating
microglial activation to suppress their deleterious effects and
promote their beneficial ones. In fact minocycline, a tetracycline
antibiotic with anti-inflammatory properties, attenuates the
development of pathology in the experimental autoimmune
encephalomyelitis (EAE) animal model of MS through its action
on microglia (Popovic et al., 2002). However, beneficial microglial
responses are activated during the development of EAE, such
as the induction of TREM-2 expression, which controls excess
inflammation and stimulates phagocytosis of myelin debris
(Takahashi et al., 2007).
Several pharmacological strategies in MS focus on the
inhibition of the peripheral immune response, and their effect
on microglial cells have been poorly investigated (Giunti et al.,
2013). In fact, therapeutic strategies designed to modulate the
innate immune response through an action on microglial cells are
underexplored (Goldmann and Prinz, 2013). Potential candidates
include the inhibitory mechanisms involved in the control
of the microglial inflammatory response. Under physiological
conditions, inhibitory mechanisms involved in neuron-glia
communication participate in the control of the microglial
inflammatory response, including CX3CL1-CXRCR1, CD172a-
CD45, CD47-CD172, and CD200-CD200R1 ligand-receptor
pairs (Tian et al., 2009; Jurgens and Johnson, 2012; Kierdorf
and Prinz, 2013). In neurological diseases, the persistence of
glial activation over time suggests a possible impairment of these
inhibitory mechanisms. In the present study we focus on the
CD200-CD200R1 system (Gorczynski, 2012; Walker and Lue,
2013). The CD200 molecule is a transmembrane glycoprotein
mainly expressed by neurons and endothelial cells in the CNS,
but that is also thought to be expressed by oligodendrocytes
and astrocytes. Its receptor CD200R1 is mainly expressed by
myeloid cells, like microglia or macrophages. CD200-CD200R1
interaction in myeloid cells results in the phosphorylation of a
NPxY motif in the cytoplasmic domain of CD200R1 (Wright
et al., 2000), which binds the phosphotyrosine-binding (PTB)
domain in the adaptor molecules downstream of tyrosine kinase
1 (Dok1) and Dok2 upon tyrosine phosphorylation. This results
in the recruitment and activation by phosphorylation of the
Ras GTPase effector enzyme (RasGAP) (Zhang et al., 2004;
Mihrshahi and Brown, 2010) and the inhibition of Ras and
downstream MAPKs (mitogen-activated protein kinases) PI3K
and ERK activation, leading to the inhibition of the production
of inflammatory cytokines.
In both the mouse and the human brain, two CD200 isoforms
are expressed by alternative mRNA splicing, a full form of
the protein (CD200full) -the most abundant isoform- and a
truncated form (CD200tr) (Borriello et al., 1998; Chen et al., 2008,
2010). CD200tr also binds to CD200R1, but does not activate
the signal transduction pathway, acting as a physiological CD200
antagonist (Chen et al., 2008, 2010). In regard to CD200R1, a
single mRNA variant has been described in the mouse brain
(Wright et al., 2000), but four mRNA variants resulting from
alternative splicing are described in the human brain (Vieites
et al., 2003). While the mouse CD200R1 mRNA encodes a
transmembrane protein, only two of the human CD200R1 mRNA
variants encode transmembrane proteins whereas the other two
encode shorter soluble proteins lacking the transmembrane and
cytoplasmic domains. Little is known of the changes occurring
in CD200 and CD200R1 expression, or in the mechanisms that
regulate this expression under physiological and pathological
conditions in the CNS, but it has been suggested that the CD200-
CD200R1 system could be a candidate therapeutic target in MS
(Koning et al., 2009b). The expression of molecules, such as
CD200, involved in the control of the inflammatory response
by microglia/macrophage, is modified in the postmortem brain
tissue of patients with MS (Koning et al., 2007, 2009a). Decreased
expression of CD200 and CD200R has been described in
postmortem brain tissue of patients with Alzheimer’s disease
(Walker et al., 2009). Several experimental approaches using
the EAE model of MS have shown that reducing the CD200-
CD200R1 interaction can aggravate the pathology (Hoek et al.,
2000; Meuth et al., 2008), while facilitating CD200R1 activation
can improve outcomes (Chitnis et al., 2007; Liu et al., 2010).
Although studies in postmortem human tissue have allowed the
characterization of the CD200-CD200R1 system at the final stages
of the pathology, data are missing on the changes occurring
in this system over time, and on their possible involvement in
the development of MS. Finally, although manipulation of the
CD200-CD200R1 interaction can modify the course of EAE, the
extent to which the CD200-CD200R1 system is modified during
EAE has not been studied to date.
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We have recently shown that CD200R1 expression is inhibited
in vitro in mouse reactive microglial cells, and that transcription
factors involved in the control of the inflammatory response
in these reactive microglia modulate CD200R1 expression
(Dentesano et al., 2012, 2014). In the present study, we aimed to
determine the dynamics of the CD200-CD200R1 system in EAE
by looking at the changes in CD200 and CD200R1 expression in
mouse CNS during the development of pathology in the context
of associated glial activation and inflammation.
MATERIALS AND METHODS
Animals
All animal experiments were performed in accordance with
the Guidelines of the European Union Council (Directive
2010/63/EU) and Spanish Government (BOE 67/8509-12) and
were approved by the Ethics and Scientific Committees of the
Spanish National Research Council (CSIC) and the University
of Barcelona. All protocols were registered at the “Departament
d’Agricultura, Ramaderia, Pesca, Alimentació i Medi Natural de la
Generalitat de Catalunya” (DARP 7065). Mice were maintained
under regulated light and temperature conditions at the animal
facilities of the Faculty of Medicine, University of Barcelona. All
efforts were made to minimize animal suffering and discomfort
and to reduce the number of animals used.
EAE Model
The EAE model used female 6 to 8-week-old C57BL/6 mice
(Harlan UK Ltd., Blackthom, UK), as previously described
(Mannara et al., 2012). Briefly, mice were immunized under
isoflurane anesthesia with a subcutaneous injection of an
encephalitogenic emulsion containing 100 µg/mouse of
myelin oligodendrocyte glycoprotein (MOG) peptide 35–55
(MOG35−55, Espikem, Italy) and 1 mg/mouse of H37R
Mycobacterium tuberculosis (Difco, USA) in 200 µl of complete
Freund’s adjuvant (CFA) (Sigma–Aldrich, St. Louis, MO, USA).
These were then called MOG-EAE mice. Sham-treated mice
were injected with a similar emulsion but without MOG35−55,
and were used as controls. These were then called CFA mice. All
mice were injected intraperitoneally with pertussis toxin from
Bordetella pertussis (500 ng/mouse, Sigma–Aldrich) at 1 and
48 h after immunization. Body weight was checked daily from
7 days post-immunization (DPI). At the same time, clinical EAE
symptoms (mobility loss and hind limb paralysis) were evaluated
according to the following score: 0 = no symptoms; 0.5 = tail
weakness; 1 = tail completely flaccid; 1.5 = low difficulty in
righting; 2 = high difficulty in righting; 2.5 = unsteady gait
and paraparesis (mild paralysis of one or two hind limbs);
3 = complete paralysis of one hind limb; 3.5 = complete
paralysis of one hind limb and mild paralysis of the other hind
limb; 4 = paraplegia (complete paralysis of two hind limbs) and
incontinence; 4.5 = paraplegia and mild paralysis of one or two
forelimbs; and 5=moribund or dead.
For evaluation of clinical EAE symptoms, we used 11 CFA and
26 MOG-EAE mice in three independent experiments. MOG-
EAE mice were killed at 28 DPI. In subsequent experiments,
CFA and MOG-EAE mice were killed at the following points
to determine cellular and molecular alterations in EAE: 9 DPI
(presymptomatic phase), 14 DPI (symptomatic phase), 21 DPI
(EAE peak) and 28 DPI (chronic phase). For mRNA and
protein expression studies, 6 CFA and 19 MOG-EAE mice
were considered, CFA mice were processed at 14 (n = 3) and
28 (n = 3) DPI, whereas MOG-EAE mice were processed
at 9 (n = 4), 14 (n = 4), 21 (n = 5), and 28 (n = 6)
DPI. Spinal cords and brains were carefully removed and
longitudinally divided into equal left and right halves, to be
processed for RNA or protein extraction, respectively. The
spinal cord was dissected into cervical, thoracic, and lumbar
regions, while the brain was dissected into mesencephalon
plus diencephalon, the rhombencephalon, and the telencephalon
regions. All samples were quickly frozen in dry ice. For histology,
in situ hybridization and immunohistochemistry 5 CFA and
11 MOG-EAE mice were considered. MOG-EAE mice were
perfused in 4% paraformaldehyde at 14 (n = 5) and 21 (n = 6)
DPI as previously described (Mannara et al., 2012), while CFA
mice were processed at 21 DPI (n = 5). Spinal cords and
brains were carefully removed, post-fixed, and cryoprotected
in a solution of 30% sucrose and 4% paraformaldehyde, and
spinal cords were also divided into cervical, thoracic and
lumbar regions. All samples were frozen in dry ice and
20 µm-thick cryostat coronal sections were obtained and stored
at−20◦C.
Histology and Immunohistochemistry
Sequential sections from CFA and MOG-EAE mice (15 and
25 µm-thick) were used for histological analysis, as described
previously (Mannara et al., 2012). Hematoxylin and eosin
staining was performed to evaluate the general status of the
tissue and the presence of cell infiltration. Luxol fast blue method
was used for staining myelin projections. Mouse sections were
processed for immunohistochemistry as described previously
(Valente et al., 2012). The primary and secondary antibodies used
are shown in Table 1. Microscopy images were obtained with
an Eclipse 1000 Nikon microscope (Nikon, Tokyo, Japan) and a
digital camera (Olympus DP72, Tokyo, Japan).
In Situ Hybridization
Digoxigenin-d-UTP (Boehringer-Mannheim, Mannheim,
Germany)-labeled antisense and sense riboprobes were obtained
using mouse CD200 cDNA (a kind gift from Prof. R. Gorczynski,
Toronto General Research Institute, Canada) and commercial
CD200R1 cDNA (OriGene, Rockville, MD, USA). In situ
hybridization was performed on mouse brain and spinal cord
sections, as described previously (Valente et al., 2005).
Quantitative Real-Time Polymerase
Chain Reaction
Total RNA was isolated from frozen tissue samples, using the
Trizol method (Tri
R©
Reagent, Sigma–Aldrich). One microgram
of RNA was reverse transcribed with random primers using
Transcriptor Reverse Transcriptase (Roche Diagnostics Scheiwz
AG, Rotkreuz, Switzerland). Then, cDNA was diluted 1/30 to
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TABLE 1 | Antibodies used in western blot assays and immunocytochemistry.
Primary antibody Species Company Dilution Secondary antibody Dilution Company
Western blot
β-Actin Mouse Sigma–Aldrich 1/40000 Goat anti-mouse HRP 1/5000 Santa Cruz Biotech.
β-Tubulin Mouse Sigma-Aldrich 1/1000 Goat anti-mouse HRP 1/5000 Santa Cruz Biotech.
CD200 Goat R&D 1/1000 Mouse anti-goat HRP 1/2000 Sigma–Aldrich
CD200R1 Goat Santa Cruz Biotech. 1/300 Mouse anti-goat HRP 1/2000 Sigma–Aldrich
Immunohistochemistry
CD200 Goat R&D 1/50 Alexa 488 donkey anti-goat 1/1000 Invitrogen
CD200 Rabbit BIOSS 1/50 Alexa 488 donkey anti-rabbit 1/1000 Invitrogen
CD200R1 Goat R&D 1/500 Alexa 488 donkey anti-goat 1/1000 Invitrogen












MBP Rat Millipore 1/1000 Biotinylated goat anti-rat 1/1000 Invitrogen
NeuN Mouse Millipore 1/500 Alexa 546 donkey anti-rabbit 1/1000 Invitrogen
CD200R1, CD200 receptor 1; GFAP, glial fibrillary acidic protein; Iba1, ionized calcium binding adaptor molecule 1; MBP, myelin basic protein; NeuN, Neuronal nuclei.
Companies: Sigma–Aldrich, St. Louis, MO, USA; R&D Systems Inc., Minneapolis, MN, USA; Santa Cruz Biotechnology, Inc., Dallas, Texas, USA; BD Pharmingen: BD
Bioscencies, San José, CA, USA; Abcam plc, Cambridge, United Kingdom; Bioss antibodies, Woburn Massachusetts, USA; Dako, Carpinteria, CA, USA; Wako Pure
Chemical Industries Ltd, Tokyo, Japan; Millipore, Bedford, MA, USA; Invitrogen Molecular Probes, Eugene, OR, USA; Vector Laboratories Inc., Burlingame, CA, USA.
perform quantitative real-time polymerase chain reaction (qRT-
PCR) with IQ SYBRGREEN SuperMix (Bio-Rad Laboratories,
Hercules, CA, USA) as previously described (Valente et al., 2012).
The primers (Integrated DNA Technologies, Leuven, Belgium)
used to amplify mouse mRNA are shown in Table 2. Relative
gene expression was calculated by the comparative Ct or 11Ct
method (Livak and Schmittgen, 2001) using CFX 2.1 software
(Bio-Rad Laboratories).
Western Blot
Mouse total protein extracts were obtained as previously
described (Valente et al., 2012). Protein quantification was
determined by Bradford assay (Bio-Rad Laboratories). Western
blot analysis of 30 µg extracts of total protein was performed
using appropriate primary and secondary antibodies (Table 1),
as previously described (Valente et al., 2012). Membranes
were developed with ECL-Plus (Amersham GE Healthcare
TABLE 2 | Primers used for qRT-PCR.
Murine
Target mRNA Accession number Forward primer (5′→3′) Reverse primer (5′→3′)
Arg1 NM_007482.3 TTGCGAGACGTAGACCCTGG CAAAGCTCAGGTGAATCGGC
Cd200full NM_010818.3 GGGCATGGCAGCAGTAGCG TGTGCAGCGCCTTTCTTTC
Cd200tr # GATGGGCAGTCTGTGGAAGTG GAGAACATCGTAAGGATGCAGTTG
Cd200r1 NM_021325.3 AGGAGGATGAAATGCAGCCTTA TGCCTCCACCTTAGTCACAGTATC
COX2 NM_011198.3 TGCAGAATTGAAAGCCCTCT CCCCAAAGATAGCATCTGGA
Gfap NM_001131020.1 AAGGTCCGCTTCCTGGAA GGCTCGAAGCTGGTTCAGTT
Iba1 NM_019467.2 GAAGCGAATGCTGGAGAAAC AAGATGGCAGATCTCTTGCC
Il1b NM_008361.3 TGGTGTGTGACGTTCCCATTA CAGCACGAGGCTTTTTTGTTG
Il10 NM_010548.2 TGAATTCCCTGGGTGAGAAG ACACCTTGGTCTTGGAGCTT
Mrc1 NM_008625.2 TCTTTTACGAGAAGTTGGGGTCAG ATCATTCCGTTCACCAGAGGG
Nos2 NM_010927.3 GGCAGCCTGTGAGACCTTTG GCATTGGAAGTGAAGCGTTTC
Socs3 NM_007707.3 GGGTGGCAAAGAAAAGGAG GTTGAGCGTCAAGACCCAGT
Tgfb NM_011577.1 TGCGCTTGCAGAGATTAAAA AGCCCTGTATTCCGTCTCCT
Tnfa NM_013693.2 TGATCCGCGACGTGGAA ACCGCCTGGAGTTCTGGAA
Rn18s∗ NR_003278.3 GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
#Chen et al., 2010; ∗reference gene; Arg1, arginase1; CD200full, full-length CD200; CD200tr, truncated CD200; CD200R1, CD200 receptor 1; CD200R1-Large, CD200R1
mRNA variants 1 and 4 (large mRNA variants); CD200R1-Short, CD200R1 mRNA variants 2 and 3 (short mRNA variants); CD200R1-V1, CD200R1 mRNA variant 1;
CD200R1-V2, CD200R1 mRNA variant 2; CD200R1-V3, CD200R1 mRNA variant 3; CD200R1-V4, CD200R1 mRNA variant 4; COX2, cyclooxygenase-2; Gfap, glial
fibrillary acidic protein; Iba1, ionized calcium binding adaptor molecule 1; Il1b, interleukin 1 beta; Il10, interleukin 10; Mrc1, mannose receptor 1; Nos2, nitric oxide
synthase 2; Socs3, suppressor of cytokine signaling 3; Tgfb, transforming growth factor beta; Tnfa, tumor necrosis factor alpha; Rn18s, 18S ribosomal RNA; RPS18,
ribosomal protein S18.
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Life Sciences Europe GmbH, Barcelona, Spain) and images
were obtained using a VersaDoc System camera (Bio-Rad
Laboratories). Data were expressed as the ratio between the band
intensity of the protein of interest and that of the loading control
(β-actin).
Data Presentation and Statistical
Analysis
Normality of data was determined by D’Agostino and Pearson
omnibus normality test. Statistical analyses were performed using
one-way analysis of variance (ANOVA) and the Dunnett post hoc
test. The Spearman correlation coefficient (r) was calculated to
measure the linear correlation between the clinical EAE score
and mRNA expression. Statistical analyses were performed using
GraphPad Prism 4.02 (GraphPad Software, Inc., La Jolla, CA,
USA). All results are presented as mean ± SEM values, unless
otherwise stated. Values of p < 0.05 were considered statistically
significant.
RESULTS
EAE Model and Glial Activation
To determine the kinetics of CD200-CD200R axis dysregulation
during EAE, we first characterized EAE in this study, because
this is known to be dependent on the facility/environment.
MOG-EAE mice showed the first clinical signs of EAE at
10 DPI, with a mean onset at 12.9 ± 0.5 DPI (Figure 1A).
The incidence of EAE was 26.1, 78.3, and 100%, at 10, 14,
and 18 DPI, respectively (Figure 1B). At 18 DPI, 13.0% of
the animals showed limp tails (score 0.5–1.0), 21.7% showed
dysfunctional motor coordination (score 1.5–2.0) and 65.2%
showed mild-to-moderate paraparesis (score 2.5–4.0). The EAE
clinical data correlated with the demyelination observed in the
spinal cord of MOG-EAE mice at 14 and 21 DPI. Thus, some
small patches of demyelination were observed in the white matter
of the dorsolateral spinal cord at 14 DPI, which became more
evident at 21 DPI (Figure 1C). Infiltrating cells were detected by
hematoxylin and eosin staining, which were evaluated by specific
lymphocyte markers in the white matter of MOG-EAE mice, and
were mainly localized around the marginal zone of demyelinated
areas (Figure 1C), close to the spinal cord surface. Some cells
were observed at 14 and 21 DPI showing B- and T-lymphocyte
markers (B220 and CD3) (Figure 1D).
Regarding glial cells, we detected significant increases in
the mRNA expressions of both the microglia/macrophage
marker Iba1 and the astroglial marker GFAP in spinal cord
regions of MOG-EAE mice at different post-immunization
times (Figure 2A), albeit with some exceptions. Larger
increases were observed in the lumbar spinal cord. Curiously,
in the presymptomatic EAE phase (9 DPI), Gfap mRNA
upregulation was observed in the cervical region. In MOG-
EAE mice, strong Iba1 immunostaining was observed in
spinal cord white matter at 14 and 21 DPI, suggesting
microglia/macrophage activation. In addition, an increase
in GFAP immunostaining was observed at 14 and 21 DPI
in spinal cord white matter, which suggested astroglial
FIGURE 1 | The experimental autoimmune encephalomyelitis (EAE)
model in C57BL/6J mice. (A) The EAE score during 28 days
post-immunization (DPI) (CFA mice, n = 11; MOG-EAE mice, n = 26). EAE
symptoms appeared at 10 DPI and the peak of EAE score was reached at
18 DPI. (B) Progression of incidence and clinical score in MOG-EAE mice.
(C) EAE histological features in the lumbar spinal cord: some areas of
demyelination (arrows in Luxol fast blue –LFB- and myelin basic protein –MBP-
labeling) were observed at 14 and 21 DPI in MOG-EAE mice when compared
with CFA mice (black arrows); infiltrates were detected by hematoxylin and
eosin staining (HEM). Scale bars: 250 µm in Luxol fast blue and MBP images,
and 200 µm in HEM staining. (D) Lymphocyte infiltrates are evident in the
lumbar spinal cord (arrows). B220-positive B-cell (green) and CD3-positive
T-cell (red) infiltrates were found at 14 and 21 DPI. Scale bar: 100 µm.
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FIGURE 2 | Glial activation in the CNS of MOG-EAE mice. (A) The mRNA expressions of Iba1 (microglial marker) and Gfap (astrocyte marker) were evaluated in
spinal cord regions by qRT-PCR during EAE, using Rn18s as the housekeeping gene. (B) Iba1 and GFAP immunoreactivity (arrows) in CFA and MOG-EAE mice
spinal cord at 14 and 21 DPI. Results from lumbar spinal cord, as representative of all spinal cord areas studied, are shown. (C) Iba1 and Gfap mRNA expressions in
brain areas of CFA and MOG-EAE mice during EAE progression. (D) Immunocytochemistry showing Iba-1 and GFAP positive cells (red) in the CA1 field of the
hippocampus (HP) and the temporal cortex (CX). Cells were counterstained with DAPI (blue). Bars represent the means ± SEM of 4–6 animals. ∗p < 0.05,
∗∗p < 0.01 vs. respective CFA; one-way ANOVA and Dunnett post-test. RE, rhombencephalon; ME/DE, mesencephalon/diencephalon; TE, telencephalon. Scale
bars: 100 µm.
activation. Figure 2B shows images from lumbar spinal
cord as representative region showing the most apparent
glial reactivity in the spinal cord. We also determined Iba1
and Gfap mRNA expression in all brain regions (Figure 2C)
of MOG-EAE mice at different post-immunization times.
Interestingly, upregulation of Iba1 mRNA could be observed
in the presymptomatic phase in mesencephalon/diencephalon
(Figure 2C). Microglial/macrophage activation was confirmed
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by Iba1 immunostaining in coronal brain sections (Figure 2D),
where reactive microglia/macrophages were detected in
the hippocampus at 14 and 21 DPI. GFAP-labeled reactive
astrocytes were also observed in hippocampal and cortical areas
(Figure 2D).
Time Course of CD200 Expression in EAE
We studied whether the immune reaction associated to MOG
injection produced changes in the expression of the inhibitory
immune receptor, CD200R1, and its ligand, CD200, in the
CNS. To this end, we determined their mRNAs and/or
protein expression in the spinal cords and brains of CFA
and MOG-EAE mice after several DPI. In MOG-EAE mice,
downregulation of Cd200full mRNA expression was observed
in the presymptomatic phase of EAE (9 DPI) in lumbar and
thoracic regions, but was observed in all spinal cord regions
during symptomatic phases, except at 28 DPI in the thoracic
region (Figure 3A). The magnitude of changes was similar among
the spinal cord regions. Less-marked alterations were observed in
the brain than in the spinal cord, with a decrease in Cd200full
mRNA expression in the mesencephalon/diencephalon, and
punctual increases in the rhombencephalon and telencephalon
(Figure 3A). This contrasted with Cd200tr mRNA expression,
which was increased in the thoracic and cervical spinal cord in the
symptomatic phase and in the mesencephalon/diencephalon and
telencephalon in the presymptomatic phase of MOG-EAE mice
(Figure 3A). Cd200full mRNA expression negatively correlated
with EAE clinical score in thoracic and cervical spinal cord areas,
while there was a positive correlation between Cd200tr mRNA
expression and the EAE clinical score in the cervical spinal cord
(Table 3). By in situ hybridization, we observed cells positive
for Cd200full mRNA with neuronal morphology only in the
ventral part of the gray matter of the spinal cords of CFA mice,
where the somas of motor neurons are localized (Figure 3B).
However, cellular Cd200full mRNA expression was noticeably
decreased in MOG-EAE mice at 14 and 21 DPI (Figure 3B).
To determine whether CD200 transcript modulation during
EAE translated to protein changes, we analyzed spinal cord
CD200 expression by western blot. The anti-CD200 antibody
used recognized amino acids 31–232 in the CD200 protein,
and consequently the full-length and truncated isoforms (45–
48 and 35–40 kDa, respectively) (Gorczynski, 2002). A main
dense band was observed at approximately 52 kDa. From 14 DPI,
there was a significant decrease in CD200 protein in the MOG-
EAE mice (Figure 3C). The decrease observed by western blot
was confirmed by CD200 immunofluorescence on spinal cord
sections (Figure 3D), where CD200 was found to co-localize with
the neuronal marker NeuN in the ventral part of the gray matter
of the spinal cord.
Time Course of CD200R1 Expression in
EAE
In MOG-EAE mice, Cd200r1 mRNA expression was strongly
upregulated in all the spinal cord regions at all symptomatic
phases, showing a clear peak at 14 DPI (Figure 4A). Induction
of Cd200r1 mRNA was also observed in the brain, but to a
lesser extent than in the spinal cord. In addition, the EAE
clinical score was positively correlated with Cd200r1 mRNA
expression, mainly in spinal cord areas (Table 3). This increased
expression was corroborated by in situ hybridization using
spinal cord sections (Figure 4B). Thus, although no Cd200r1
positive cells were detected in the CFA mice, they were clearly
observed in MOG-EAE mice at both 14 and 21 DPI. Cells
positive for Cd200r1 mRNA were mainly localized to the white
matter, mostly in areas of demyelination and infiltration in the
lateral part of the dorsal spinal cord. Nevertheless, scattered
CD200R1 and Iba1 positive cells were also observed in more
distal areas. Western blotting of spinal cord total protein showed
an increase in CD200R1 in protein extracts of MOG-EAE mice
at 14 and 21 DPI (Figure 4C). The cellular localization of
CD200R1 protein was then analyzed by immunohistochemistry
(Figure 4D). Few CD200R1-positive cells were observed in the
spinal cords of CFA mice, and this number increased markedly
in MOG-EAE mice in the areas where cells positive for Cd200r1-
mRNA-were found. In most cells, CD200R1 co-localized with the
microglial/macrophage marker Iba1.
Inflammatory Response in EAE
As the CD200-CD200R1 interaction is involved in the control
of the inflammatory response in microglial cells, we analyzed
the inflammatory context in which changes in CD200 and
CD200R1 expression were observed. We studied the time
course of pro- and anti-inflammatory molecule expression
during the development of EAE using qRT-PCR. For classical
pro-inflammatory M1 markers, we analyzed Nos2, Il1b, and
Tnfa (Figures 5A,B). In the spinal cords of MOG-EAE mice, the
respective genes showed mRNA expression profiles characterized
by markedly peaked expression at 14 DPI (Figure 5A). In the
brain, an increase in Nos2 mRNA was also observed at 14 DPI,
particularly in the mesencephalon/diencephalon, while Il1b
mRNA was significantly upregulated in the rhombencephalon
and mesencephalon/diencephalon (Figure 5B). By contrast,
Tnfa mRNA upregulation was observed in all brain areas at
several times after immunization (Figure 5B), and notably
in both the mesencephalon/diencephalon and telencephalon
in the presymptomatic phase (9 DPI). We also analyzed
COX2 mRNA expression, an M1/M2 marker, and found
its levels significantly upregulated in all spinal cord areas
during the symptomatic phases in MOG-EAE mice (i.e.,
14–28 DPI). A significant increase in COX2 mRNA expression
was also observed in all brain areas, but to a lesser extent
than in the spinal cord (Figure 5C). In addition, COX2
mRNA upregulation was significantly increased in the
telencephalon during the presymptomatic phase of EAE
(9 DPI) (Figure 5C).
We analyzed the following M2 genes as anti-inflammatory
M2 markers: Arg1, Il10, Mrc1, Socs3, and Tgfb (Figure 6). Arg1
mRNA was strongly upregulated in spinal cord regions at 14 DPI
(Figure 6A), while more moderate increases were found in all
brain areas (Figure 6B). However, we also observed Arg1 mRNA
induction during the presymptomatic phase in the telencephalon.
For Il10 mRNA expression, we observed expression induction
in spinal cord and brain regions between 14 and 28 DPI
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FIGURE 3 | Time course of CD200 expression in EAE. (A) Full-length Cd200 (Cd200full) and truncated Cd200 (Cd200tr) mRNAs were evaluated in spinal cords
and brains by qRT-PCR during EAE, using Rn18s as the housekeeping gene. Bars are the means ± SEM of 4–6 animals. ∗p < 0.05, ∗∗p < 0.01 vs. respective CFA;
one-way ANOVA and Dunnett post-test. (B) In situ hybridization of Cd200full mRNA in the spinal cord showing Cd200full-positive cells (arrowheads) in the ventral
gray matter. (C) Expression of CD200 protein in the spinal cord by western blot using β-actin as the loading control. Bars are the means ± SEM of 4–6 animals.
∗p < 0.05, ∗∗p < 0.01 vs. respective CFA; one-way ANOVA and Dunnett post-test. A representative western blot is shown. (D) Double immunofluorescence of
CD200 (green) and NeuN (red) in the gray matter of the spinal cord (arrows). Cells were counterstained with DAPI (blue). Results from lumbar spinal cord, as
representative of all spinal cord areas studied, are shown in (B–D). RE, rhombencephalon; ME/DE, mesencephalon/diencephalon; TE, telencephalon. Scale bars:
100 µm.
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TABLE 3 | Correlation between EAE severity and Cd200full, Cd200tr or Cd200r1 mRNA expression in symptomatic MOG-EAE mice.
Spinal cord BRAIN
Target mRNA Lumbar (n = 15) Thoracic (n = 19) Cervical (n = 19) RE (n = 18) ME/DE (n = 14) TE (n = 20)
Spearman r Spearman r Spearman r Spearman r Spearman r Spearman r
Cd200full −0.4312 −0.7037∗∗∗ −0.6862∗∗ −0.0042 −0.0203 −0.1676
Cd200tr −0.3424 −0.0803 +0.7212∗∗∗ +0.4648 +0.5252∗∗ −0.1130
Cd200r1 +0.7501∗∗ +0.7154∗∗∗ +0.8161 ∗∗∗ +0.3961 +0.6120∗ −0.0008
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
(Figure 6). The largest increase was observed in lumbar spinal
cord at 14 DPI. In addition, Il10 mRNA expression was observed
in the cervical spinal cord, mesencephalon/diencephalon, and
telencephalon during the presymptomatic phase. Mrc1 mRNA
expression was strongly upregulated in lumbar spinal cord, but
significant increases were observed in the other spinal cord areas
and brain tissue at several symptomatic phases (Figure 6). Socs
3 expression was mainly upregulated by 14 DPI in spinal cord
and brain areas, but also during the presymptomatic phase in
the brain (Figure 6B). Tgfb mRNA expression was significantly
upregulated in the spinal cord during the symptomatic phase, but
only became significant in the brain at 14 DPI (Figure 6).
Finally, we analyzed the correlation between EAE severity and
pro- and anti-inflammatory mRNA expression in symptomatic
MOG-EAE mice, which showed that the EAE clinical score was
positively correlated with the expression levels of both pro- and
anti-inflammatory genes in spinal cord, especially in the lumbar
region, and brain areas, mainly in the rhombencephalon and
mesencephalon/diencephalon (Table 4).
DISCUSSION
Alterations in neuronal-glial and/or glial–glial crosstalk may
contribute to glial activation in MS, and changes in either
neuronal or glial cells could trigger this process. In turn, the
resulting functional phenotype will determine the beneficial
or detrimental role of microglial cells. Various inhibitory
mechanisms, involving both soluble signals and ligand-receptor
pairs, coexist to control the pro-inflammatory response of
microglial cells under physiological conditions. The presence of
glial activation in MS suggests that these mechanisms have been
overloaded, implicating them as potential therapeutic targets.
In the present study of the dynamics of CD200 and CD200R1
expression in the mouse CNS of an EAE model, we show that
changes in the inhibitory CD200-CD200R1 system are already
observed at presymptomatic EAE stages, in association with
glial activation, with these changes preceding the inflammatory
response that accompanies the onset of clinical signs.
The interaction between CD200 and the microglial inhibitory
receptor CD200R1 is postulated to be a mechanism involved
in controlling the microglial inflammatory response in healthy
brain tissue (Tian et al., 2009; Jurgens and Johnson, 2012;
Kierdorf and Prinz, 2013). However, CD200 and CD200R1
expression were altered at presymptomatic and symptomatic
phases in the CNS of mice that developed EAE, suggesting
compromised control of the microglial inflammatory response
from early pathological stages. Regarding the CD200 ligand, we
looked at the expression of the two Cd200 mRNA variants,
Cd200full and Cd200tr, in the mouse brain and spinal cord.
Cd200tr mRNA encodes a protein lacking part of the N-terminal
domain that is critical for CD200-CD200R1 interaction and
CD200R1 stimulation (Hatherley and Barclay, 2004), so acts as
an endogenous antagonist of CD200R1 (Chen et al., 2008, 2010).
Consequently, the ratio of Cd200full to Cd200tr expression in a
tissue may regulate the CD200-CD200R1 interaction. Cd200full
mRNA expression was clearly reduced in the spinal cords of
MOG-EAE mice during EAE, even during presymptomatic
stage, while Cd200tr mRNA expression increased during the
symptomatic phase. These changes may decrease the ratio
of CD200full to CD200tr, reducing the inhibitory input to
microglial/macrophage cells. A sustained decrease in CD200
protein levels was also detected after onset of EAE in the spinal
cord. Cd200full mRNA and CD200 protein expression were
localized in the cell bodies of motor neurons in the ventral
gray matter by in situ hybridization and immunohistochemistry,
respectively. Interestingly, no CD200 expression was detected
in the dorsal gray matter, where interneurons are located.
In brain areas, mRNA expression of both CD200 isoforms
were altered, but to a lesser extent than in the spinal cord.
Curiously, though, there was a clear increase in Cd200tr mRNA
expression in brain areas before EAE onset. Together, these
results show that the immune reaction induced by MOG35−55
administration changed the expression of CD200, suggesting
that early motor neuron dysfunction promotes the inflammatory
response.
Stimulation of CD200R1 by CD200 activates a signal
transduction pathway that inhibits pro-inflammatory gene
expression (Zhang et al., 2004). The presence of altered
CD200 expression in EAE therefore suggests that mechanisms
controlling the inflammatory response are compromised.
Previous studies have shown that the manipulation of CD200
expression or function modifies the development of EAE. In this
sense, EAE is more severe in CD200−/− than in wild-type mice
(Hoek et al., 2000) and the clinical signs of EAE are attenuated in
mice that overexpress CD200 (Chitnis et al., 2007). In addition,
mice administered anti-CD200 blocking antibody develop a
more severe EAE (Meuth et al., 2008). Thus, it is plausible that
CD200 levels influence the course of pathology in EAE, and the
decreased CD200 expression we observed in MOG-EAE mice,
which was already detected at the presymptomatic phase, will
probably facilitate the development of pathology. However, it
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FIGURE 4 | Time course of CD200R1 expression in EAE. (A) Cd200r1 mRNA was evaluated in the spinal cord and brain by qRT-PCR during EAE, using Rn18s
as the housekeeping gene. Bars are the means ± SEM of 4–6 animals. ∗p < 0.05, ∗∗p < 0.01 vs. respective CFA; one-way ANOVA and Dunnett post-test. (B) In
situ hybridization of Cd200r1 mRNA in the spinal cord. Cd200r1-positive cells (arrowheads) were detected in MOG-EAE mice. (C) CD200R1 protein expression in
the spinal cord by western blot using β-actin as the loading control. Bars are the means ± SEM of 4–6 animals. ∗∗p < 0.01 vs. respective CFA; one-way ANOVA and
Dunnett post-test. A representative western blot is shown. (D) Double immunofluorescence of CD200R1 (green) and Iba1 (red) in white matter of the spinal cord
(arrowheads). Results from lumbar spinal cord, as representative of all spinal cord areas studied, are shown in (B–D). RE, rhombencephalon; ME/DE,
mesencephalon/diencephalon; TE, telencephalon. Scale bars: 100 µm.
must also be true that the remaining CD200 expression retains
a significant functional effect because EAE is more severe when
CD200 is completely absent (Hoek et al., 2000) or blocked
(Meuth et al., 2008).
Regarding CD200R1, the spinal cords of MOG-EAE mice
showed a strong induction of Cd200r1 mRNA expression after
the onset of EAE, and this remained elevated during EAE.
Cd200r1 mRNA expression also increased in the brain after
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FIGURE 5 | Time-course expression of pro-inflammatory genes in EAE. The mRNAs of the pro-inflammatory genes Nos2, Il1b, and Tnfa were evaluated in the
spinal cord (A) and brain (B) by qRT-PCR during EAE. (C) The mRNA expression of COX2, pro- and anti-inflammatory gene, was evaluated in the spinal cord and
brain by qRT-PCR. Rn18s was used as the housekeeping gene. Bars are the means ± SEM of 4–6 animals. ∗p < 0.05, ∗∗p < 0.01 vs. respective CFA; one-way
ANOVA and Dunnett post-test. RE, rhombencephalon; ME/DE, mesencephalon/diencephalon; TE, telencephalon.
EAE induction, though to a lesser extent than in the spinal
cord. Accordingly, while CD200R1 protein levels were very low
in the CNS of control mice, they were markedly increased in
the spinal cords of MOG-EAE mice. We clearly localized the
CD200R1 mRNA and immunosignal in an increased population
of Iba1-positive microglia/macrophages to parenchyma in the
dorsal spinal cord white matter of MOG-EAE mice, in and
around the areas of demyelination and infiltration. Liu et al.
(2010) showed that giving a CD200R1 agonist reduced disease
severity, demyelination, and axonal damage in a mouse EAE
model, suggesting that CD200R1 stimulation and the resulting
inhibition of the inflammatory response positively affect the
outcome of EAE. The increase in CD200R1 expression observed
in EAE may, therefore, act to compensate for the loss of function
in the CD200-CD200R1 system that follows decreased CD200
expression.
CD200R1 agonist treatment has been shown to inhibit the
production of pro-inflammatory cytokines in activated glial cells
in culture (Liu et al., 2010; Hernangómez et al., 2012; Lyons et al.,
2012). Therefore, the increased CD200R1 expression observed
in the MOG-EAE mice in our model could be a compensatory
response to limit the expression of pro-inflammatory markers.
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FIGURE 6 | Time-course expression of anti-inflammatory genes in EAE. The mRNAs of anti-inflammatory genes Arg1, Il10, Mrc1, Socs3, and Tgfb were
evaluated in the spinal cord (A) and brain (B) by qRT-PCR during EAE. Rn18s was used as the housekeeping gene. Bars are the means ± SEM of 4–6 animals.
∗p < 0.05, ∗∗p < 0.01 vs. respective CFA; one-way ANOVA and Dunnett post-test. RE, rhombencephalon; ME/DE, mesencephalon/diencephalon; TE,
telencephalon.
Frontiers in Cellular Neuroscience | www.frontiersin.org 12 May 2017 | Volume 11 | Article 129
fncel-11-00129 May 2, 2017 Time: 15:18 # 13
Valente et al. CD200-CD200R1 Expression in EAE
TABLE 4 | Correlation between EAE severity and pro- and anti-inflammatory mRNA expression in symptomatic MOG-EAE mice.
Spinal cord Brain
Target mRNA Lumbar (n = 15) Thoracic (n = 19) Cervical (n = 19) RE (n = 19) ME/DE (n = 15) TE (n = 20)
Spearman r Spearman r Spearman r Spearman r Spearman r Spearman r
Pro-inflammatory
Nos2 +0,7519∗∗ +0,3713 +0,3207 +0,4562∗ +0,7929∗∗∗ +0,3781
Il1b +0,6002∗ +0,4715∗ +0,1238 +0,3153 +0,6340∗ +0,2534
Tnfa +0,6522∗∗ +0,4652∗∗ +0,5802 +0,6612∗∗ +0,2138 +0,5035∗
Pro-/Anti-inflammatory
COX2 +0,7120∗∗ +0,2331 +0,3595 +0,0447∗ +0,5262∗ +0,6190∗∗
Anti-inflammatory
Arg1 +0,3352 +0,5050∗ +0,3514 +0,4742∗ +0,3764 +0,4023
Il10 +0,8352∗∗∗ +0,4473 +0,1915 +0,4968∗ +0,5974∗ −0,1840
Mrc1 +0,7465∗∗ +0,2755 +0,5664∗ +0,4209∗ +0,6556∗ +0,6635∗∗
Socs3 +0,7193∗∗ +0,7007∗∗ +0,4175 +0,4869∗ +0,8642∗∗∗ +0,3547
Tgfb +0,0857 +0,5641∗ +0,5710∗ +0,5875∗∗ +0,7052∗∗ +0,5684∗∗
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
To asses this, we correlated the time course of changes in
Cd200 and Cd200r1 mRNA expression in the CNS of MOG-EAE
mice with the evolution of the inflammatory response during
EAE, and evaluated the RNA expressions of pro-inflammatory
M1 (Nos2, Il1b, Tnfa) and anti-inflammatory M2 (Arg1, Il10,
Mrc1, Socs3, and Tgfb) markers. In spinal cord regions, the
mRNA expression of pro- and anti-inflammatory genes was
strongly induced after EAE onset, but only anti-inflammatory
gene expression remained elevated thereafter (except for Arg1).
A decrease in Cd200full mRNA expression in the spinal cord
preceded the inflammatory response, which was attenuated in the
presence of a maintained increase in Cd200r1 mRNA expression.
However, an inflammatory response also developed in brain
areas, though they did not show overall alterations in Cd200full
mRNA and Cd200R1 mRNA as in the spinal cord. Curiously,
we observed a significant induction of anti-inflammatory genes
in brain areas during the presymptomatic phase. The expression
pattern of COX2, which is classified as a marker of M1 and
M2 phenotypes (David and Kroner, 2011; Chhor et al., 2013;
Franco and Fernández-Suárez, 2015), has shown a similar
expression pattern to the M2 markers in our MOG-EAE mice.
A sustained increase in the expressions of CD200R1 and anti-
inflammatory markers could reflect an attempted compensatory
response aimed at resolving the inflammatory process (Colton,
2009).
Regarding the clinical score for EAE, a negative correlation
was noted with Cd200full mRNA expression in thoracic,
cervical but not lumbar spinal cord areas in symptomatic
MOG-EAE mice, while a positive correlation was found
with Cd200r1 mRNA expression in all spinal cord areas. In
addition, a positive correlation was also observed between
the clinical score for EAE and Cd200tr mRNA expression in
cervical spinal cord. These results suggest that the magnitude
of changes in CD200R1 expression in spinal cord reflects the
severity of EAE. The magnitude of changes in the mRNA
expression of both pro- and anti-inflammatory genes also
positively correlated to the severity of EAE spinal cord
(mainly lumbar) and brain (mainly rhombencephalon and
mesencephalon/diencephalon), and suggests the coexistence
of M1 and M2 phenotypes in microglia/macrophages
in EAE.
CONCLUSION
Our results show that the expressions of CD200 and
CD200R1 in the CNS are modified during EAE. Postmortem
samples from patients with MS are usually only able to
show the final stages of disease, and cannot illuminate
the changes that occur early in the pathogenesis. In this
study, we demonstrated that there was a decrease in
CD200 expression before the onset of clinical symptoms
in EAE. This suggests that alterations in CD200 expression
might also occur in the early stages of MS, which may be
responsible for downregulated control of microglial/macrophage
activation, thereby stimulating the inflammatory response
and contributing to the development of the pathology.
By contrast, there was a subsequent increase in CD200R1
expression that possibly represented a compensatory response
to re-establish control of the inflammation. The fact that
CD200R1 expression was increased points to this receptor
as a potential therapeutic target for the regulation of
neuroinflammation. Indeed, we consider that CD200R1
agonists are promising molecules that should be developed to
modulate neuroinflammation and the resulting neurotoxicity in
neurological disease.
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